BioMarin Pharmaceutical Inc. (BMRN)

Market Cap	13.63B
Revenue (ttm)	2.85B
Net Income (ttm)	426.86M
Shares Out	190.78M
EPS (ttm)	2.21
PE Ratio	32.37
Forward PE	16.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,209,732
Open	72.59
Previous Close	72.83
Day's Range	70.89 - 72.67
52-Week Range	60.63 - 94.85
Beta	0.33
Analysts	Buy
Price Target	94.00 (+31.58%)
Earnings Date	Apr 23, 2025

About BMRN

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NA...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 23, 1999
• Employees: 3,040
• Stock Exchange: NASDAQ
• Ticker Symbol: BMRN
• Website: https://www.biomarin.com

Financial Performance

In 2024, BioMarin Pharmaceutical's revenue was $2.85 billion, an increase of 17.97% compared to the previous year's $2.42 billion. Earnings were $426.86 million, an increase of 154.62%.

Analyst Forecast

According to 22 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is $94.0, which is an increase of 31.58% from the latest price.

Price Target

$94.0

(31.58% upside)

Analyst Consensus: Buy